Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II –IIIA (8th edition TNM classification) primary lung cancer after curative surgery

Epidermal growth factor receptor (EGFR) mutation is a driver gene mutation in pulmonary adenocarcinoma [1]. EGFR mutations account for more than half of the driver gene mutations in pulmonary adenocarcinoma in Japan, and 85 –90% of EGFR mutations are exon 19 deletion mutations (Ex19) or exon 21 L858R point mutations (Ex21) [2,3]. Proliferative cell signals from mutated EGFR strongly influence the survival of EGFR-mutant lung cancer cells, and a class of molecular-targeted therapeutic drugs, known as EGFR-tyrosine kin ase inhibitor (TKI), is used to curb these signals and enhance the anticancer effects [4].

Source: Lung Cancer - November 8, 2021 Category: Cancer & Oncology Authors: Tetsuya Isaka, Hiroyuki Ito, Haruhiko Nakayama, Tomoyuki Yokose, Haruhiro Saito, Hiroyuki Adachi, Jun Miura, Shunsuke Shigefuku, Akitomo Kikuchi, Yasushi Rino Source Type: research